



ASX ANNOUNCEMENT

25 MARCH 2022

Placement of Entitlement Offer Shortfall

On 21 February 2022, Chimeric Therapeutics Limited (ASX:CHM) (**Chimeric or Company**) announced the details of an accelerated non-renounceable 1 for 3.15 entitlement offer (**Entitlement Offer**).

Chimeric announced the successful completion of the Institutional component of the Entitlement Offer on 23 February 2022, which raised approximately \$7.4 million, and announced the completion of the Retail Entitlement Offer on 23 March 2022, which raised approximately \$4.3 million.

The Company, in consultation with its Lead Manager Bell Potter Securities Ltd and Co-Manager Baker Young Limited, subsequently conducted a Retail Entitlement Offer Shortfall Placement (**Placement**) under the same terms as the Entitlement Offer.

The Company has completed the Placement, raising approximately \$2.7 million (before costs of the Placement). Approximately 15,900,296 fully paid ordinary shares (**New Shares**) at \$0.17 per share (**Offer Price**) together with approximately 15,900,296 attaching options exercisable at \$0.255 expiring 31 March 2024 (**New Options**) will be issued to successful applicants under the Placement.

Chimeric will not seek to conduct any further shortfall placements relating to the Entitlement Offer announced on 21 February 2022. The total raised under the Entitlement Offer (including the Placement) amounts to approximately \$14.4 million (before costs of the Entitlement Offer and Placement).

Since the announcement of the Entitlement Offer, Chimeric has continued to make important advancements across its business and cell therapy portfolio. It announced positive final results from the Phase 1 trial of its CORE NK Platform in both blood cancers and solid tumours (7 March 2022), partnered with Be The Match BioTherapies to expand clinical development of the CLTX CAR T program (4 March 2022), and featured in an article on CDH17 CAR T preclinical data in the prestigious Nature Cancer journal (23 March 2022).

“We’re extremely pleased with the progress the business has made since listing in early 2021, expanding the portfolio with very promising assets and announcing positive early data,” said Executive Chairman Paul Hopper.

“We thank investors for their support during this capital raising and remain eager to deliver value to our shareholders moving forward.”

For personal use only



Indicative timetable¹

Indicative dates for the Placement are set out below.

Event	Date
Settlement via Delivery Versus Payment (DvP) for New Shares to be issued under the Placement	30 March 2022
Allotment via DvP of New Shares and New Options issued under the Placement, normal ASX trading commences	31 March 2022

Electronic access

The prospectus (**Prospectus**) under which the Entitlement Offer was made is available at www.chimerictherapeutics.com.

Authorised on behalf of the Chimeric Therapeutics board of directors by Chairman Paul Hopper.

Important information

This document must not be distributed or released in the United States.

ABOUT CHIMERIC THERAPEUTICS

Chimeric Therapeutics, a clinical stage cell therapy company and an Australian leader in cell therapy, is focused on bringing the promise of cell therapy to life for more patients with cancer. We believe that cellular therapies have the promise to cure cancer not just delay disease progression.

To bring that promise to life for more patients, Chimeric's world class team of cell therapy pioneers and experts is focused on the discovery, development, and commercialization of the most innovative and promising cell therapies.

CHM 1101 (CLTX CAR T) is a novel and promising CAR T therapy developed by scientists at the City of Hope Medical Centre in California for the treatment of patients with solid tumours. CHM 1101 is currently being studied in a phase 1 clinical trial in recurrent/ progressive glioblastoma. A 2nd CLTX CAR T phase 1 clinical trial is planned to begin in 2022 in additional solid tumours.

CHM 2101 (CDH17 CAR T) is a novel, 3rd generation CDH17 CAR T invented at the University of Pennsylvania. CHM 2101 (CDH17 CAR T) is currently in preclinical development with a planned phase 1 clinical trial in 2022 in Neuroendocrine Tumours, Colorectal, Pancreatic and Gastric Cancer.

¹ All dates are indicative only and subject to change. Chimeric reserves the right to withdraw or vary the timetable without notice.

For personal use only



Recently Chimeric announced the addition of the CORE-NK platform, a clinically validated, off the shelf natural killer (NK) cell therapy platform to their portfolio (CHM 0201). From the CORE-NK platform, Chimeric will initiate development of four new next generation NK and CAR NK assets with plans for phase 1 clinical trials to begin in 2023 in solid tumours and blood cancers.

Chimeric Therapeutics continues to be actively engaged in further developing its oncology pipeline with new and novel cell therapy assets that will bring the promise of cell therapy to life for more patients with cancer.

CONTACT

Investors

Jennifer Chow
Chief Executive Officer and Managing Director
Chimeric Therapeutics
T: + 1 9087238387
E: jchow@chimerictherapeutics.com
W: www.chimerictherapeutics.com

Paul Hopper
Executive Chairman
Chimeric Therapeutics
T: + 61 406 671 515
E: paulhopper@lifescienceportfolio.com

Media

Matthew Wright
NWR Communications
P: +61 451 896 420
E: matt@nwrcommunications.com.au

For personal use only